Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess theSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in HealthyParticipants

Next Previous
Trial Profile

A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess theSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in HealthyParticipants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vemircopan (Primary) ; Ciprofloxacin
  • Indications Autoimmune disorders; Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease

Most Recent Events

  • 26 Jul 2019 Status changed from recruiting to completed.
  • 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, based on the results from this study the company plans to advance ACH-5228 into Phase 2 clinical trials in multiple diseases.
  • 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, the company expects to submit an IND application to the U.S. Food and Drug Administration supporting clinical development for ACH-5228 in the fourth quarter of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top